gastroenteritis%20-%20parasitic
GASTROENTERITIS - PARASITIC
Frequently, patients with gastrointestinal parasitic infections do not have any signs and symptoms that are specific for parasitic infections (eg fever, malaise, fatigue, sweating, wt loss, anorexia, edema, pruritus).
Some patients may be asymptomatic.
Gastrointestinal symptoms, if present, include diarrhea, abdominal pain, dysentery, flatulence, jaundice, rectal prolapse, dyspepsia, malabsorption, vomiting and biliary colic. 

Gastroenteritis - Parasitic Drug Information

Drug Information

Indication: Urogenital trichomoniasis in both genders. All forms of amoebiasis (intestinal & extraintestinal disease &...

Indication: Amoebic liver abscess, anaerobic bacterial infections. Tab: Symptomatic & asymptomatic trichomoniasis, int...

Indication: Appendicitis, cholecystitis, peritonitis, liver, lung & brain abscess, post-op wound infection; puerperal ...

Indication: Trichomoniasis in males & females; amoebiasis, vag, intra-abdominal, skin, gynaecologic, bone & joint ...

Indication: Whipworm, pinworm, hookworm & roundworm infestation.

Indication: Roundworm, whipworm, pinworm or threadworm, hookworm, Strongyloides stercoralis, Taenia solium, Taenia saginat...

Indication: Infestations of all common worms eg, roundworm, whipworm, hookworm, pinworm, threadworm & tapeworm.

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Apr 2019
Using preventive zinc and micronutrient powder supplementation does not appear to improve growth in children, a recent study has found.
Roshini Claire Anthony, 28 Sep 2020

A 4-week course of amoxicillin-clavulanate in children with protracted bacterial bronchitis (PBB) does not improve cough resolution rates compared with a 2-week course, according to a study from Australia. However, the longer course may significantly extend time to first cough exacerbation.

Audrey Abella, 14 Oct 2020
Findings from the phase IIa T1GER study revealed the therapeutic potential of the monoclonal antibody golimumab for children and young adults with type 1 diabetes (T1D).